Clinical features of hypersensitivity reactions to oxaliplatin: A 10-year experience

Oncology

Volumn 76, Issue 1, 2008, Pages 36-41

  Polyzos, Aristides ^a   Tsavaris, Nikolas ^a   Gogas, Hellen ^a   Souglakos, John ^b   Vambakas, Lambros ^b   Vardakas, Nikolaos ^b   Polyzos, Kostas ^a   Tsigris, Christos ^a   Mantas, Demetrios ^a   Papachristodoulou, Antonios ^a   Nikiteas, Nikolas ^a   Karavokyros, John G ^a   Felekouras, Evangelos ^a   Griniatsos, John ^a   Giannopoulos, Athanasios ^a   Kouraklis, Gregory ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Hypersensitivity reactions; Oxaliplatin; Platinum compound

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; STEROID;

ADULT; AGED; ANAPHYLAXIS; ARTICLE; BILE DUCT CARCINOMA; BLOOD PRESSURE; BREAST CARCINOMA; BRONCHOSPASM; CHEST TIGHTNESS; CLINICAL FEATURE; COLORECTAL CANCER; CONTROL GROUP; DRUG WITHDRAWAL; ERYTHEMA; ERYTHRODERMA; FACE EDEMA; FEMALE; HEMOLYTIC ANEMIA; HUMAN; HYPERSENSITIVITY REACTION; HYPOTENSION; LARYNX SPASM; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION SYSTEM; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PRURITUS; RETROSPECTIVE STUDY; SIDE EFFECT; SINGLE DRUG DOSE; STEROID THERAPY; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT DURATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DRUG HYPERSENSITIVITY; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STOMACH NEOPLASMS;

EID: 56449104887     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000178163     Document Type: Article

References (36)

1. Waynarowski JM, Chapman WG, Napier C, et al: Sequence and region specificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol 1998;54:770-777.
2. Raymond E, Faivre S, Woynarowski JM, et al: Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998;25(suppl 5):4-12.
3. De Gramont A, Vignoud J, Tournigand C, et al: Oxaliplatin with high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997;33:214-219.
4. André T, Boni C, Mounedji-Boudiaf L, et al: Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-2351.
5. Chollet P, Bensmaine MA, Brienza S, et al: Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 1996;7:1065-1070.
6. Monnet I, Brienza S, Hugret F, et al: Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). Eur J Cancer 1998;34:1124-1127.
7. Germann N, Brienza S, Rotarski M, et al: Preliminary results of the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients. Ann Oncol 1999;10:351-354.
8. Misset JL: Oxaliplatin in practice. Br J Cancer 2005;39:966-999.
9. Cassidy J, Misset JL: Oxaliplatin-related side effects: characteristics and management. Semin Oncol 2002;29:11-20.
10. Shlebak AA, Clark PI, Green JA: Hypersensitivity and cross-reactivity to cisplatin and analogues. Cancer Chemother Pharmacol 1995;35:349-351.
11. Markman M, Kennedy A, Webster K, et al: Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 1999;17:1141-1145.
12. Polyzos A, Tsavaris N, Kosmas C, et al: Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology 2001;61:129-133.
13. Brandi G, Pantaleo MA, Galli C, et al: Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer 2003;89:477-481.
14. Thomas RR, Quinn MG, Schuler B, Grem JL: Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer 2003;97:2301-2307.
15. Gowda A, Goel R, Berdzik J, et al: Hypersensitivity reactions to oxaliplatin: incidence and management. Oncology (Williston Park) 2004;18:1671-1675.
16. Maindrault-Goebel F, André T, Tournigand C, et al: Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer 2005;41:2262-2267.
17. Siu SW, Chan RT, Au GK: Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol 2006;17:259-261.
18. Lee MY, Yang Mh, Liu JH, et al: Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication. Support Care Cancer 2007;15:89-93.
19. Souglakos J, Androulakis N, Syrigos K, Polyzos A, et al: FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil, and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomized phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006;94:798-805.
20. Androulakis N, Syrigos K, Polyzos A, Aravantinos, et al: Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study. Hellenic Oncology Research Group. Cancer Invest 2005;23:9-12.
21. Androulakis N, Aravantinos G, Syrigos K, Polyzos A, et al: Oxaliplatin as first-line treatment in inoperable biliary tract carcinoma: a multicenter phase II study. Oncology 2006;70:280-284.
22. Souglakos J, Syrigos K, Potamianou A, Polyzos A, et al: Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as firstline treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial. Ann Oncol 2004;15:1204-1209.
23. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, version 3.0, DCTD, NCI, NIH, DHHS, 31 March 2003. http://ctpe.cancer.gov (accessed 1 August 2005).
24. Santini D, Tonini G, Salerno A, et al: Idiosyncratic reaction after oxaliplatin infusion. Ann Oncol 2001;12:132-133.
25. Trisolini R, Lazzari AL, Tassinari D, et al: Acute lung injury associated with 5-fluouracid and oxaliplatin combined chemotherapy. Eur Respir J 2001;18:243-245.
26. Bhargava P, Gammon D, McCormick MJ: Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer 2004;100:211-212.
27. Mis L, Fernando NH, Hurwitz HI, Morse MA: Successful desensitization to oxaliplatin. Ann Pharmacother 2005;39:966-969.
28. Garcia-Velasco A, Sotto Claude MA, Lozoya C, et al: Hypersensitivity reactions to oxaliplatin: incidence and predictive value of skin tests. Proc 14th ICACT, Paris, February 2003, p 213.
29. Garufi C, Cristaudo A, Vanni B, et al: Skin testing and hypersensitivity reactions to oxaliplatin. Ann Oncol 2003;14:497-498.
30. Meyer L, Zuberbier T, Worm M, et al: Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule. J Clin Oncol 2002;20:1146-1147.
31. Goldberg A, Confino-Cohen R, Fishman A, et al: A modified, prolonged desensitization protocol in carboplatin allergy. J Allergy Clin Immunol 1996;98:841-843.
32. Lin CC, Lobo FM: Successful desensitization to oxaliplatin in a patient with oxaliplatin hypersensitivity (abstract 880). J Allergy Clin Immunol 2003;111:S289.
33. Garufi C, Vaglio S, Brienza S, et al: Immunohemolytic anemia following oxaliplatin administration. Ann Oncol 2000;11:497.
34. Hofheinz RD, Nguyen XD, Buchheidt D, et al: Two potential mechanisms of oxaliplatin-induced haemolytic anaemia in a single patient. Cancer Chemother Pharmacol 2004;53:276-277.
35. Giacchetti S, Perpoint B, Zidani R, et al: Phase III randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-147.
36. Levi F, Zidani R, Vannetzel JM, et al: Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 1994b;86:1608-1617.